Gerald McMahon, a seasoned pharma executive, has been appointed chief executive of STORM Therapeutics Ltd, a UK company working in the field of RNA epigenetics. This involves developing small molecule drugs that target RNA modification enzymes to treat cancer and other diseases. Dr McMahon was most recently CEO of Harpoon Therapeutics Inc. a US immuno-oncology company. Prior to this he was CEO of Kolltan Pharmaceuticals, an antibody-drug developer that was acquired by Celldex Therapeutics Inc in 2016. Dr McMahon has also been senior vice president for oncology at AstraZeneca’s Medimmune. He received his BS in biology and PhD in biochemistry and genetics from Rensselaer Polytechnic Institute in the US.
STORM Therapeutics announced the appointment on 7 September 2022.
Copyright 2022 Evernow Publishing Ltd